A5035600520- Liver physiology and pathology
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Glycosylation and Glycoproteins Research
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- MicroRNA in disease regulation
- Glioma Diagnosis and Treatment
- Additive Manufacturing and 3D Printing Technologies
- Protein purification and stability
- PI3K/AKT/mTOR signaling in cancer
- Microtubule and mitosis dynamics
- Complement system in diseases
- Circular RNAs in diseases
- HIV Research and Treatment
- Cancer Research and Treatments
- biodegradable polymer synthesis and properties
- Immunodeficiency and Autoimmune Disorders
- Radiopharmaceutical Chemistry and Applications
Symphogen (Denmark)
2017-2019
Harvard University
2007-2008
Predicting the outcome of immunotherapy is essential for efficient treatment.The recent clinical success increasingly changing paradigm cancer treatment.Accordingly, development immune-based agents accelerating and number in global immuno-oncology pipeline has grown 60-70% over past year.However, despite remarkable efficacy some patients, only few achieve a lasting response.Treatment failure can be attributed to poorly immunogenic tumors that do not attract tumor infiltrating lymphocytes...
Early B cell development is characterized by stepwise, ordered rearrangement of the immunoglobulin (Ig) heavy (HC) and light (LC) chain genes. Only one two alleles these genes used to produce a receptor, phenomenon referred as allelic exclusion. It has been suggested that pre–B receptor (pre-BCR) signals are responsible for down-regulation VDJH-recombinase machinery (Rag1, Rag2, terminal deoxynucleotidyl transferase [TdT]), thereby preventing further on second HC allele. Using mouse model,...
Discovery of therapeutic antibodies is a field intense development, where immunization rodents remains major source antibody candidates. However, high orthologue protein sequence homology between human and rodent species disfavors generation against functionally conserved binding epitopes. Chickens are phylogenetically distant from mammals. Since chickens generate restricted set germline genes, the possibility adapting Symplex discovery platform to chicken immunoglobulin genes combining it...
Increased MET activity is linked with poor prognosis and outcome in several human cancers currently lacking targeted therapies. Here, we report on the characterization of Sym015, an antibody mixture composed two humanized IgG1 antibodies against nonoverlapping epitopes MET. Sym015 was selected by high-throughput screening searching for mixtures superior growth-inhibitory MET-dependent cell lines. Synergistic inhibitory comprising observed cancer lines harboring amplified locus confirmed vivo...
Anticalin® proteins have been proven as versatile clinical stage biotherapeutics. Due to their small size (∼20 kDa), they harbor a short intrinsic plasma half-life which can be extended, e.g., by fusion with IgG or Fc. However, for antagonism of co-immunostimulatory Tumor Necrosis Factor Receptor Superfamily (TNFRSF) members in therapy autoimmune and inflammatory diseases, monovalent, pharmacokinetically optimized Anticalin protein format that avoids receptor clustering therefore potential...
<p>Supplementary methods</p>
<div>Abstract<p>Increased MET activity is linked with poor prognosis and outcome in several human cancers currently lacking targeted therapies. Here, we report on the characterization of Sym015, an antibody mixture composed two humanized IgG<sub>1</sub> antibodies against nonoverlapping epitopes MET. Sym015 was selected by high-throughput screening searching for mixtures superior growth-inhibitory MET-dependent cell lines. Synergistic inhibitory comprising observed...
<p>Supplementary figure 1. Sym015 inhibits viability of cell lines in a synergic manner; Supplementary 2. The antibodies Hu9338 and Hu9006 bind to 2nd or 3rd blades MET block HGF binding; 3. induces internalization degradation MKN-45 cells; 4. EBC-1 5. 6. signaling by 7. motility EBC-1</p>
<p>Supplementary methods</p>
<p>Supplementary figure 1. Sym015 inhibits viability of cell lines in a synergic manner; Supplementary 2. The antibodies Hu9338 and Hu9006 bind to 2nd or 3rd blades MET block HGF binding; 3. induces internalization degradation MKN-45 cells; 4. EBC-1 5. 6. signaling by 7. motility EBC-1</p>
<div>Abstract<p>Increased MET activity is linked with poor prognosis and outcome in several human cancers currently lacking targeted therapies. Here, we report on the characterization of Sym015, an antibody mixture composed two humanized IgG<sub>1</sub> antibodies against nonoverlapping epitopes MET. Sym015 was selected by high-throughput screening searching for mixtures superior growth-inhibitory MET-dependent cell lines. Synergistic inhibitory comprising observed...
Abstract Introduction: The clinical success of immune-checkpoint inhibitors in oncology has stimulated development immune-based agents and revolutionized treatment for many types cancer. With only a subpopulation patients benefiting from immuno-therapeutic agents, the predictive vivo biomarker response is critical to enhance therapeutic efficacy such agents. level immune infiltration tumors seems reflect outcome immuno-therapy, failure usually attributed so-called “cold” that do not attract...
Abstract Inhibition of immunologic checkpoints like Programmed Cell Death 1 (PD-1) has shown clinical efficacy in a broad range cancers by improving or restoring T-cell activity. Anti-PD-1 antibodies show great promise treating cancer malignances when administered alone combination with other immune activating approaches. However, high protein sequence identity between human and mammalian species used for antibody generation often disfavor against functionally conserved epitopes, prevents...